CD147-CART / Air Force Medical University - LARVOL DELTA

CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. (PubMed, Cancer Lett) - "NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt mice were used to establish a T-ALL xenograft model and CD147-CAR T cells conferred robust protection against T-ALL progression and significantly improved survival in mice. Overall, we found that CD147 is a potential antigen target of CAR T cell therapy for T-ALL."

CAR T-Cell Therapy • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • BSG • CCR7 • PRKDC

Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. (PubMed, Transl Oncol) - "Importantly, CD147-CART cells have strong anti-tumor activity against NSCLC cells in vivo in both CDX and PDX models and no adverse side effects. Our findings show that CD147-CART immunotherapy for NSCLC is safe and effective, which is an ideal and promising medical patch for treating NSCLC."

CAR T-Cell Therapy • IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BSG

CD147-CART Cells in Patients With Recurrent Malignant Glioma. (clinicaltrials.gov) - P1; N=31; Recruiting; Sponsor: Xijing Hospital; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=34; Recruiting; Sponsor: Xijing Hospital; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open

CD147-CART Cells in Patients With Recurrent Malignant Glioma. (clinicaltrials.gov) - P1; N=31; Active, not recruiting; Sponsor: Xijing Hospital

Clinical • New P1 trial